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ABSTRACT:  The characterization of the underlying GALC gene lesions was performed in 30 
unrelated patients affected by Krabbe disease, an autosomal recessive leukodystrophy caused by 
the deficiency of lysosomal enzyme galactocerebrosidase. The GALC mutational spectrum 
comprised 33 distinct mutant (including 15 previously unreported) alleles. With the exception of 4 
novel missense mutations that replaced evolutionarily highly conserved residues (p.P318R, 
p.G323R, p.I384T, p.Y490N), most of the newly described lesions altered mRNA processing. 
These included 7 frameshift mutations (c.61delG, c.408delA, c.521delA, 
c.1171_1175delCATTCinsA, c.1405_1407delCTCinsT, c.302_308dupAAATAGG, 
c.1819_1826dupGTTACAGG), 3 nonsense mutations (p.R69X, p.K88X, p.R127X) one of which 
(p.K88X) mediated the skipping of exon 2, and a splicing mutation (c.1489+1G>A) which induced 
the partial skipping of exon 13. In addition, 6 previously unreported GALC polymorphisms were 
identified. The functional significance of the novel GALC missense mutations and polymorphisms 
was investigated using the MutPred analysis tool. This study, reporting one of the largest genotype-
phenotype analyses of the GALC gene so far performed in a European Krabbe disease cohort, 
revealed that the Italian GALC mutational profile differs significantly from other populations of 
European origin. This is due in part to a GALC missense substitution (p.G553R) that occurs at high 
frequency on a common founder haplotype background in patients originating from the Naples 
region.  ©2010 Wiley-Liss, Inc. 
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INTRODUCTION 
  Krabbe disease, also known as globoid-cell leukodystrophy (GLD; MIM# 245200), is an autosomal recessive 
disorder resulting from the deficiency of galactocerebrosidase (GALC; E.C. 3.2.1.46), a lysosomal enzyme 
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involved in the catabolism of galactosylceramide, a cerebroside located mainly in the myelin sheath. GALC 
defects lead to the accumulation of a cytotoxic metabolite (galactosylsphingosine or psychosine) which results in 
the apoptosis of myelin-forming cells [Wenger et al., 2001]. 
  The majority of patients with Krabbe disease (around 85%-90% of cases) have the infantile form of the 
condition, presenting with extreme irritability, spasticity and developmental delay before the age of six months, 
with death occurring before the age of two. The remaining 10-15% of patients have a late-onset form of the 
disease, the onset of symptoms occurring between the age of 6 months and the fifth decade, and with slower 
disease progression. In the infantile form of Krabbe disease, the child, who appears normal for the first few months 
post-partum, presents with frequent crying and irritability, feeding difficulties, arrest/regression of motor and 
mental development, as well as seizures in some cases. Severe motor and mental deterioration follows, leading to 
decerebration.  Peripheral neuropathy is typically present. In the late-onset forms of the disease, individuals can be 
clinically normal until weakness, vision loss and intellectual regression become evident; however, adult onset 
patients may show spastic paraparesis as the only symptom.  Disease severity is variable, even within families. 
Further differentiation between late-infantile (onset age, six months to three years, severe clinical course), juvenile 
(onset age, three to eight years; more gradual progression lasting for years), and the adult-onset forms, is 
commonly employed (http://www.genetests.org) [Wenger, 2008]. Nerve conduction velocity studies have been 
reported to be normal in some adults with an enzymatically confirmed diagnosis. Brain magnetic resonance 
imaging (MRI) usually reveals deep white matter abnormalities consistent with a demyelinating process that 
involves the brainstem and cerebellum. Computed Tomography (CT) scans may reveal hyperdensity indicative of 
calcification involving the cerebellum, thalami, caudate, corona radiata and brainstem. 
  The galactosylceramidase gene (GALC; MIM# 606890], spanning 60 kb of genomic DNA on chromosome 
14q31, comprises 17 exons and encodes a 3.8 kb mRNA (Figure 1). Two in-frame ATG translational start sites, 
located in exon 1 (Figure 1), give rise to distinct isoforms of GALC which are both translated. Although 
translational initiation at these alternative ATG codons yields protein precursors with 42-residue (NP_000144.2) or 
26-residue leader sequences respectively, both precursors are processed to the 669-residue mature enzyme [Chen 
et al., 1993; Sakai et al., 1994; Luzi et al., 1995a]. The precursor protein, estimated to have a molecular mass of 
80-kDa, is proteolytically processed into 30- and 50-kDa fragments in the extracellular medium. Neither the 50- 
nor the 30-kDa fragment, expressed in vitro in COS cells, have been demonstrated to possess GALC activity, an 
indication that the entire structure is probably necessary for enzymatic activity and that fragments expressed 
separately cannot subsequently associate to form an active enzyme [Chen et al., 1993; Chen and Wenger, 1993; 
Sakai et al., 1994, Nagano et al. 1998]. 
  Although the GALC gene was identified more than 15 years ago, fewer than 80 mutations have been reported 
as a cause of Krabbe disease [http://www.hgmd.org; Stenson et al., 2009] and relatively few papers have addressed 
the issue of a genotype-phenotype relationship in this disorder. Clinical phenotypes can however differ quite 
markedly between individuals with the later-onset forms of the disease, including siblings harbouring the same 
GALC genotypes. The GALC mutational profile differs between European and Japanese Krabbe disease patients; 
thus, whilst the most common large deletion, c.1161+6532_polyA+9kbdel (IVS10del30kb) plus three other 
mutations [c.1586C>T, c.1700C>T, c.1472delA (1538C>T, 1652A>C, 1424delA)] together account for about 60% 
of alleles in patients of European ancestry with the classic infantile form [Kleijer et al., 1997; Wenger et al., 1997], 
these lesions are absent in their Japanese counterparts. By contrast, ~30% of Japanese GALC alleles associated 
with the infantile form of the disease possess either c.683_694del12insCTC or c.2002A>C (635_646del12insCTC 
and 1954A>C) [Xu et al., 2006]. It should be noted that GALC mutations have traditionally been described on the 
basis of their amino acid position in the mature enzyme, with p.M17 being designated as the first residue. Current 
HGVS nomenclature recommendations however require proteins to be numbered from the first methionine of the 
complete 42-residue signal sequence. Hence, throughout this article, we ascribe HGVS designations to specific 
amino acid residues, with the traditional designations given in parentheses. 
The median prevalence of Krabbe disease is estimated to be ~1 in 100,000 births (1.00 x 10
-5) with wide 
variations between countries: 1.35 in Netherlands, 1.21 in Portugal,  1.00 in Turkey, 0.71 in Australia, and 0.40 in 
the Czech Republic [Poupětová et al., 2010].  However, two quite separate inbred communities in Israel (the Druze 
and Moslem Arab populations) have an extremely high prevalence of the infantile form (about 1 in 100-150 live 
births), due to two non-identical mutations, c.1796>G and c.1630G>A (1748T>G and 1582G>A), respectively 
[Rafi et al., 1996]. The founder mutation c.169G>A (121G>A) is responsible for the other known Krabbe disease 
‘hotspot’ in Catania (Sicily), this time associated with the late-onset form of the disease [Lissens et al., 2007]. E1896  Tappino et al. 
 In Italy, accurate epidemiological data for lysosomal disorders (LSDs) are not available owing to both the 
geographically wide dispersion of the patients between the various collaborating clinical/laboratory centres and the 
lack of any national register of rare diseases. However, the Gaslini laboratory has extensive experience in the 
analysis and diagnosis (both antenatal and postnatal) of LSDs, including Krabbe disease, going back over 35 years. 
Additionally, biobanked cell lines (“Cell line and DNA Biobank from patients affected by Genetic Diseases” at 
http://dppm.gaslini.org/biobank/) have enabled us to put together, between 1976 and 2009, unique collections of 
clinical samples and related data from a large series of families involving a total of 970 patients with 41 diverse 
LSD types/subtypes. Using the Biobank database, we have estimated the relative prevalence of Krabbe disease as 
~4% of the total number of LSD patients (data not shown). Although the examined time period and number of 
LSD types/subtypes differ slightly between published studies, our prevalence data are comparable to those 
reported from  the Czech Republic and Australia (3.3% and 5%, respectively) [Poupetova et al., 2010; Meikle et 
al., 1999]. 
To date, the Krabbe disease collection within the Biobank includes 36 families. We have previously reported 
eight unrelated patients, in five of whom the second allele had remained undetermined [Selleri et al., 2000]. Here, 
we have characterized the underlying GALC gene lesions in a total of 30 unrelated Krabbe disease patients, in an 
analysis which included the complete genotyping of two patients from the previous study [Selleri et al., 2000]. 
This study therefore reports one of the largest mutational analyses of the GALC gene so far performed in a 
Caucasian population affected by Krabbe disease. It is apparent that the Italian mutational GALC profile differs 
significantly from other populations of European origin (http://www.genetests.org) [Wenger, 2008]. 
 
MATERIALS AND METHODS 
Patients 
The present series comprises a total of 30 unrelated patients with Krabbe disease. The diagnosis was suspected 
upon clinical evaluation and was supported by neuroimaging and neurophysiological findings. Most (27/30) 
patients underwent neuroradiological studies (brain MRI in 22/27 and CT scan in 13/27); nerve conduction 
velocity studies were performed in 14/30 patients. The characteristics of these patients and the main clinical 
findings are summarized in Table 1.  
A diagnosis of Krabbe disease was confirmed by enzymatic assay in homogenates of leukocytes or fibroblast 
cell lines using either tritium-labelled [H
3] galactosylceramide (until 2004) or 6-hexadecanoylamino-4-
methylumbelliferone-beta-D-galactoside (post-2004) as substrates. GALC activity values are provided for each 
patient in Table 1. 
The patients in this series were diagnosed over a period of more than 30 years. The present study has been made 
possible thanks to the availability of the corresponding patient fibroblast/lymphoblast cell lines and/or DNA 
samples, cryopreserved within the laboratory “Cell Line and DNA Biobank from Patients affected by Genetic 
Diseases”. Following ethical guidelines, all samples obtained for analysis and storage required prior written 
informed consent using a form approved by the Local Ethics Committee. 
Cell culture 
Fibroblast and lymphoblast cells were cultured according to standard procedures. The cell lines were cultured 
and maintained in RPMI medium (EuroClone, Gibco, Paisley, UK) containing 15% FCS and 
penicillin/streptomycin, in a humidified atmosphere containing 5% CO2 at 37°C. 
Molecular analysis 
Genomic DNA was extracted using standard methods from cultured fibroblasts or lymphoblasts derived from 
the affected individuals and from peripheral blood leukocytes of the available family members. GALC gene exons 
and exon–intron boundaries were PCR amplified using specific primers designed by reference to the genomic 
sequence (GenBank-EMBL Accession No. NC_000014.8).  
We initially screened for the large common Caucasian 30-kb GALC gene deletion 
(c.1161+6532_polyA+9kbdel) in all DNA samples, using three PCR primers in accordance with the previously 
reported method [Luzi et al., 1995b]. In the next step, a total of 16 PCR amplimers were tested on each patient, 
exons 2–3 being amplified simultaneously, as reported in Supp. Table S1. PCR amplification conditions were as GALC Gene Mutations  E1897 
 
follows: initial denaturation 2 min at 94°C, followed by 35 cycles amplification, denaturation at 94°C for 30 sec, 
annealing from 58°C to 62°C for 30 sec, and extension at 72°C for 40 sec using AmpliTaq DNA Polymerase 
(Applied Biosystems, Foster City, CA). Details of PCR-product sizes and annealing temperatures are reported in 
Supp. Table S1. 
Total RNA was extracted from patient fibroblasts/lymphoblasts using an RNeasy mini kit (QIAGEN, 
Courtaboeuf, France) and reverse transcribed by means of an Advantage RT-for-PCR kit (BD Biosciences 
Clontech, Mountain View, CA, USA). RT-PCR was performed using sets of primers designed by reference to the 
GALC mRNA sequence (GenBank accession No. NM_000153.2).  The RT-PCR set of primers employed is given 
in Supp. Table S1 together with the temperature profiles and expected product sizes. RT-PCR amplification 
conditions were as follows: initial denaturation 2 min at 98°C, followed by 30 cycles of amplification, denaturation 
at 98°C for 20 sec, annealing from 59°C to 65°C for 30 sec, and extension at 72°C for 30 sec, using Phusion High-
Fidelity DNA Polymerase (Finnzymes, Keilaranta, Finland). These PCR products were cloned into the TOPO TA 
Cloning KIT (with pCR2.1-TOPO vector) (Invitrogen, San Diego, CA) according to the manufacturer’s 
instructions. 
Sequence analysis of PCR and RT-PCR products was performed in the forward and reverse directions using the 
ABI PRISM Big Dye Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA). Sequences were 
analyzed on an ABI PRISM 3700 DNA Analyzer. Sequence alterations were confirmed by sequencing duplicate 
PCR products and/or by digesting PCR products with the specific restriction endonuclease whose recognition site 
had been concomitantly altered. If a given alteration had neither created nor destroyed a restriction site, PCR 
amplification was carried out by PCR-mediated site-directed mutagenesis that artificially introduced a new 
restriction enzyme cleavage site (Supp. Table S2 [Schwartz et al., 1991].  
The issue of whether the novel GALC sequence alterations detected were causative mutations or neutral 
polymorphisms was addressed by (i) searching dbSNP (http://www.ncbi.nlm.nih.gov/SNP) for their presence, (ii) 
screening 100 alleles from healthy control subjects for each alteration, and (iii) employing the MutPred program 
[Li et al., 2009; Mort et al., 2010] (see below). 
MutPred analysis of GALC mutations and polymorphisms  
The likely pathogenicity of missense mutations (and non-synonymous polymorphisms) identified in the human 
GALC gene was assessed by means of a computational model termed MutPred [Li et al., 2009; Mort et al., 2010]. 
MutPred was designed to model changes of structural and functional sites between wild-type and mutant protein 
sequences. Hence, MutPred can be used to generate hypotheses regarding the underlying molecular mechanism(s) 
responsible for disease pathogenesis 
Haplotype analysis 
Segregation analysis of the identified polymorphisms was performed on all patients in the series including all 
patients coming from the same geographic area (Campania region). 
Mutation nomenclature 
All mutations are described according to current mutation nomenclature guidelines 
(http://www.hgvs.org/mutnomen), ascribing the A of the first ATG translational initiation codon as nucleotide +1 
[den Dunnen and Antonarakis, 2000; den Dunnen and Paalman, 2003]. Traditional amino acid residue numbering 
has nevertheless also been provided in parentheses. 
 
 
  Table 1: Clinical, instrumental and molecular data encountered in 30 unrelated GLD patients
Pt 
no.  Sex  Age at 
onset  Symptoms at onset 
Neurological findings Neuroradiologic findings 
NCVs  Sibling
♣ 
GALC 
enzymatic 
activity § 
(% normal)
GALC  Genotype**  Age at 
exam  Spasticity/ Other signs  MR I finding s 
(WM changes) 
CT scan f indi ngs 
(C alcific ation/ 
WM changes) 
1  F  1m  Failure to thrive  7m  +/ Truncal hypotonia   +  ND  Slowed    4.4  [c.1161+6532_ polyA+9kbdel]+[?] 
2  F  3m  Psychomotor regression  5m  +/ Truncal hypotonia   + (Hypomyel) ND  Slowed    8.2  [p.L469YfsX22]+[p.L469YfsX22]# 
3  M  3m  Muscular hypertonia  6m  +/Nystagmus  +  +/ +  ND    0.3  [ p.G553R]+[p.G553R]# 
4  M  3m  Irritability, muscular hypertonia  5m  +/Truncal hypotonia  +  ND  ND    14.7  [p.S 303F]+[p.G553R ] 
5  M  3m  Muscular hypertonia. seizures  6m +/ Truncal hypotonia ND +/ +  ND yes 18.5 [p.E136EfsX35]+[p.E136EfsX35]
6  F  3m  Irritability, psychomotor regression  7m  +/ Truncal hypotonia  +  ND  S lowed    21.7  [p.K359AfsX3]+[p.Y567S ] 
7  F  3m  Nystagmus, psychomotor regression  6m +/Truncal hypotonia, poor tendon reflexes + ND  Slowed 3.2 [ p.Y174LfsX3]+[c.1161+6532_ polyA+9kbdel]
8 M  4m  Irritability,  muscular  hypertonia  6m  +/Nystagmus  +  ND  S lowed yes  0  [p.E130K]+[p.N295T]# 
9  M  4m  Muscular hypertonia  6m  +/Truncal hypotonia, poor tendon reflexes ND  +/ +  ND    11.1  [p.H391IfsX65]+[p.H391IfsX65] 
10 M  4m  Muscular  hypertonia  8m +/ Truncal hypotonia  ND -/+  N D y e s 5 [p.T529M]+[c.1161+6532_ polyA+9kbdel]
11  F  4m  Muscular hypertonia  6m  +/ Truncal hypotonia   + (Hypomyel) ND  Slowed    8.4  [p.A21RfsX5]+[p.G553R] 
12  F  4m  Irritability, muscular hypertonia  5m  +/ Truncal hypotonia   + (Hypomyel) +/+  ND  yes  0  [p.Y314C ]+[c.1161+6532_ polyA+9kbdel]# 
13  M  5m  Psychomotor regression  6m  +/Truncal hypotonia  +  ND  ND  yes  0  [p.F596SfsX16]+[p.F596SfsX16]# 
14  F  5m  Psychomotor regression, seizures  7m  +/ Truncal hypotonia   + (Hypomyel) ND  Slowed    0  [p.G553R]+[p.G553R] 
15  F  5m  Irritability, muscular hypertonia  7m +/ Truncal hypotonia  + (Hypomyel) +/+  ND 0 [p.N295T]+[c.1161+6532_ polyA+9kbdel]
16  F  5m  Psychomotor regression  7m  +/ Truncal hypotonia   ND  ND  ND    8.3  [p.R127X]+[p.G553R]## 
17  F 5m  Muscular  hypertonia 10m +/ Truncal  hypotonia ND ND  ND 4.8 [p.K88X]+[p.Y490N]#
18 M  5m  Psychomotor regression  9m +/ Truncal hypotonia + +/ +  ND 8.8 [p.R396L]+[c.1161+6532_ polyA+9kbdel]
19 M  5m  Psychomotor  regression  8m  +/ Truncal hypotonia   +  ND  ND  yes 18.2  [p.G553R]+[p.G553R]# 
20 M  5m  Muscular hypertonia  7m  +/ Truncal hypotonia   +  ND  ND  yes 9.7  [p.L634X]+[c.1489+1G>A] 
21 F  5m  Psychomotor regression  8m  +/ Truncal hypotonia   +  ND  ND  yes 0.71  [p.E130K]+[p.Y490N] 
22  M  8m  Psychomotor regression  11m  +/ Truncal hypotonia   +  -/ +  ND  yes  13.2  [p.G102GfsX5]+[?] 
23 M  8m Psychomotor  regression  11m +/ Truncal hypotonia ND -/+  N D y e s 0 .2 6 [p.D187V]+[p.G323R ]
24  F 1 0m Psychomotor  regression  12m +/ Truncal hypotonia + -/+  S lo we d y e s 0 [p.G59R]+[?]#
25  M  11m  Irritability, muscular hypertonia  13m +/ Truncal hypotonia  ND -/+ S lowed 10.1 [p.I250T]+[p.R 396W]
26  F  3y 6m  Gait disturbances and frequent falls  4y +/ Ataxia, poor tendon reflexes + ND  Slowed 5 [p.G286D]+[c.1161+6532_ polyA+9kbdel]#
27  F  3y 6m  Gait disturbances and frequent falls  3y 8m  +/ Ataxia  +  -/ +  Normal   NA  [p.R69X]+[p.I384T] 
28 M  4y  Gait disturbances and frequent falls  4 y +/Nystagmus ND ND Slowed 13 [p.N295T]+[p.G609GfsX6]
29  F  4y  Reduced visual acuity  5y 9m  +/-  +  -/ +  Normal yes  0  [p.R79H]+[p.G553R] 
30  M  26y  Gait disturbances and frequent falls  30y  +/-  +  ND  Slowed    5  [p.G286D]+[p.P318R] 
Legend: Pt= Patient;  m= month(s); y= year(s); #Genotype confirmation by parental DNA analysis; ## only mother’s DNA available; ND: Not Done; N=Normal; NA: Not Available **GenBank-EMBL accession no. NM_000153.2 and no. NP_000144.2; 
Hypomyel= hypomyelination; MRI= Magnetic resonance imaging, WM=white matter; CT= Computed tomography; NCVs= nerve conduction velocity study; 
♣indicates presence of other affected patients in the family; §Owing to the use of different  
assay methods and tissue samples, as reported in the Materials and Methods, enzyme activity values are expressed as a percentage of average control values. 
 
 Tappino et al.  E1898  
E1899  Tappino et al. 
   
RESULTS AND DISCUSSION 
A comprehensive clinical evaluation, facilitated by the results of a range of diagnostic procedures including 
neuroradiological, neurophysiological and enzymatic testing, was performed on 30 unrelated patients affected by 
Krabbe disease prior to characterization at the molecular genetic level. The clinical characteristics of these 30 
patients and the main neuroradiological/ neurophysiological findings are summarized in Table 1. Apart from 
patient #2, of Moroccan origin, and patient #9, belonging to an itinerant Roma family, all patients were of Italian 
origin. 
 
Clinical aspects 
As reported in Table 1, 21 patients (pts) were classified as having the infantile form of Krabbe disease (age at 
onset ranging from 1 to 5 months) while 9 were considered to have late-onset forms of the disease. In this latter 
group were 4 patients with the late-infantile form (age at onset ranging from 8 to 11 months), 4 patients with the 
juvenile form (age at onset ranging from 3 years 6 months to 4 years) and one adult-onset patient (onset at age 26 
years). Except for the youngest patient who presented at 1 month of age simply with failure to thrive, muscular 
hypertonia (11/21) and psychomotor regression (9/21) variably associated with irritability (5/21) were the main 
presenting symptoms in the infantile-onset patients. Seizures and nystagmus were also observed at disease onset in 
two infantile patients (#5 and #7). Psychomotor regression was the presenting symptom in 3/4 patients with the 
late-infantile form, whereas irritability and muscular hypertonia occurred in the remaining patients from this 
group. Gait disturbances and frequent falls were the presenting symptoms in 4/5 patients with the juvenile (pts #26, 
#27, #28) and adult forms (pt #30) of the disease, whereas reduced visual acuity was the presenting symptom in 
the remaining case (pt #29). 
Table 1 also reports the findings at neurological examination for all subjects, at variable age after disease onset, 
who invariably exhibited spasticity irrespective of the age at onset, variably associated with truncal hypotonia, 
nystagmus, ataxia and poor tendon reflexes. CT scans revealed white matter hypodensity in all 13 patients who 
underwent examination; this was associated with calcification in 6 patients (5/6 in the thalami, in one case in the 
periventricular white matter). Brain MRI revealed white matter changes in all studied patients which were 
consistent with hypomyelination in 5 cases (Table 1). Interestingly, this latter finding may represent a feature of 
lysosomal storage disorders with onset in the first months of life, when the process of myelination is particularly 
active, indicating that neuronal storage disorders may be primarily responsible for central nervous system 
hypomyelination [Di Rocco et al., 2005]. Nerve conduction velocity studies were slowed in 12/14 analyzed 
patients, but normal in 2 subjects with the juvenile form (pts #27 and #29) of the disease. 
GALC gene mutations in the Italian population 
The  GALC gene was investigated by sequencing analysis in all 30 unrelated Krabbe disease patients. As 
reported in Supp. Table S1, all 17 exons and most of the flanking intronic regions were analyzed. Additionally, the 
sequence analysis was extended to part of the 5’ untranslated region as well as of the untranslated region (Supp. 
Table S1). Table 1 summarizes the 27 distinct mutant genotypes encountered in this 30-patient series. Apart from 7 
(23%) of the patients found to be homozygous for rare [p.G553R (G537R), p. F596SfsX16 (F580Sfs)] or novel 
[p.E136EfsX35, p.H391IfsX65, p.L469YfsX22] mutations, the remainder were rare compound heterozygotes, 
including 3 patients in whom the second mutant allele could not be identified. Among this latter group, 7 patients 
possessed the common large deletion of European origin (c.1161+6532_polyA+9kbdel) in trans to rare missense 
mutations p.G286D (G270D), p.N295T (N279T), p.Y314C (Y298C), p.R396L (R380L), p.T529M (T513M), a 
new frameshift (p.Y174LfsX3), or a still-unidentified mutation. As shown in Table 2, the GALC mutational profile 
was highly heterogeneous, being characterized by a total of 33 distinct mutant alleles including 15 previously 
unreported alleles; three mutant alleles still remain to be identified. Apart from 4 novel missense mutations 
(p.P318R, p.G323R, p.I384T, p.Y490N), 73% of the newly described mutations were expected to affect mRNA 
processing. These comprised 7 frameshift mutations resulting from 3 microdeletions (c.61delG, c.408delA, 
c.521delA), 2 indels (c.1171_1175delCATTCinsA, c.1405_1407delCTCinsT) and 2 microduplications 
(c.302_308dupAAATAGG, c.1819_1826dupGTTACAGG), respectively; 3 nonsense mutations (p.R69X, p.K88X, E1900  Tappino et al. 
p.R127X); and a splicing mutation at the donor site of intron 13 (c.1489+1G>A) which induced the partial 
skipping of exon 13. Figure 1 depicts the location of the various mutations detected in relation to the GALC gene 
and its protein product. It is evident that the GALC mutations associated with severe clinical phenotypes are spread 
throughout the gene without any preferential clustering within the sequence encoding the 30-kD subunit of the 
mature GALC protein, thought to be critical for the synthesis of catalytically active enzyme [Rafi et al., 1995 and 
1996]. 
 
 
Figure 1. Distribution of the detected mutations and polymorphisms in relation to the GALC gene and GALC polypeptide. In 
the top half of the diagram (A), the map of the GALC gene depicts the positions of the seventeen exons (dark green boxes 
numbered 1 to 17) and associated unnumbered introns (gray lines). In the bottom half of the diagram (B), the schematic 
representation of the polypeptide shows the 26-amino acid signal (leader) sequence, and the two protein subunits (50-52 kDa 
and 30 kDa) predicted to be proteolytically processed from the precursor protein. All mutations encountered in this patient 
series are given in (A) above the gene schema, all polymorphisms below. Novel mutations and polymorphisms reported here 
are denoted in red and violet respectively. HGVS nomenclature guidelines stipulate amino acid numbering from the first 
methionine of the 42-residue signal sequence. Hence, HGVS nomenclature was used for the mutations and the 
polymorphisms reported here (with the traditional designations given in parentheses).  
Relative frequencies of the GALC mutations and evidence for a founder effect involving the p.G553R (G537R) 
mutation 
  In agreement with previous studies on individuals of European ancestry (http://www.genetests.org) [Wenger, 
2008], the large deletion (c.1161+6532_polyA+9kbdel) was confirmed to be the most frequent GALC mutation in 
the Italian population (taking together 6 previously reported deletion alleles [Selleri et al., 2000] with the 7 
deletion alleles from the present series). However, while in other populations this large deletion has been shown to 
have a higher frequency, being respectively 52% of disease alleles in Dutch patients [Kleijer et al., 1997] and 44% 
of disease alleles in patients with Northern European ancestry [Luzi et al., 1995b; Rafi et al., 1995], in our series 
we found that this same deletion [c.1161+6532_polyA+9kbdel] barely accounts  for 18% of disease alleles in our 
own series. Moreover, our findings contrast with the three other common mutations [p.T529M (T513M), p.Y567S 
(Y551S) and c.1472delA (1424delA)], expected to account for ~15% of GALC alleles in the European population 
(http://www.genetests.org) [Wenger, 2008]; in our series, the two missense mutations were noted only once each 
(corresponding to 3.2% of alleles) whereas the microdeletion c.1472delA was not detected in our series at all. 
Instead, the second most frequent allele was p.G553R (G537R), previously only reported in one other family GALC Gene Mutations  E1901 
 
originating in southern Italy [De Gasperi et a1., 1999]. Since all seven patients harbouring p.G553R (G537R) 
(Table 1, pts #3, #4, #11, #14, #16, #19, #29) shared a common geographical origin around Naples (Campania 
region, southern Italy), we analysed their haplotype backgrounds. Among the various identified polymorphisms, it 
was evident that two very rare SNP alleles, namely rs74073730 [c.1072C>T (1024C>T)] and rs74076317 
[c.1338+23T>C (1290+23T>C)], were exclusively present in all 7 p.G553R-bearing patients (Supp. Table S3). 
Both SNP alleles, originally identified by massively parallel sequencing [Bentley et al., 2008], are extremely rare; 
dbSNP gives their heterozygosity as ‘not known’ 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=rs74073730). Hence the degree of linkage 
disequilibrium between the rare SNP alleles and the p.G553R disease allele could not be formally measured. 
However, we did exclude the presence of the rare SNP alleles in the remainder of the Krabbe disease patients, 
including three other individuals from the Campania region, who carried different GALC mutant genotypes (Table 
1, pts #13, #22, #24.). It is therefore likely that the p.G553R (G537R) mutation occurred on the rs74073730(T) - 
rs74076317(C) haplotype background of a common founder ancestor. Identity-by-descent would account for the 
unexpectedly high number of an otherwise extremely rare GALC mutation in Italian Krabbe disease patients. 
   In addition to the putative pathological mutations, a total of 24 GALC polymorphisms were identified within 
either the exons, introns or 5’ untranslated region (5’ UTR). Novel SNPs were noted in the 5’ UTR (1), within the 
coding region (2) and in the introns (3) (Figure 1; Supp. Table S3). The allele frequencies of the new variants, 
derived from 200 normal Italian controls, are given in Supp. Table S3. 
MutPred analysis  
    In an attempt to establish the functional relevance or otherwise of the novel GALC  missense mutations 
detected, we employed the in silico analysis tool, MutPred [available at http://mutdb.org/profile/; Li et al., 2009; 
Mort et al., 2010]. To assess the predictive power of this bioinformatic approach, the analysis was performed on 
both the newly identified missense mutations and the previously reported deleterious missense mutations. For the 
known pathological missense mutations listed in Table 2, MutPred successfully predicted all 18 (probability 
threshold >0.65) to be deleterious and generated confident in silico hypotheses for 39% (7 out of 18) of these 
mutations. Further investigation of the 4 novel missense mutations (p.P318R, p.G323R, p.I384T, p.Y490N) 
identified in the present study, indicated all four to have a high probability (>0.68) of being deleterious; in silico 
hypotheses for the underlying mechanism were generated for two of them. Thus, the novel missense mutation 
p.P318R is predicted to impact upon protein structure in terms of both solvent accessibility (P = 0.0179) and 
secondary structure (loop → helix; P = 0.0259) whereas the novel missense mutation p.Y490N is predicted to 
disrupt a phosphorylation site at this residue (P = 0.0245).  
  By contrast, none of the missense polymorphisms listed in Supp. Table S3, were predicted to be deleterious 
(probability threshold < 0.65). However, it should be noted that, according to MutPred, both the novel missense 
polymorphism p.A21P and the previously identified missense polymorphism [p.T641A (T625A)] have 
probabilities of being deleterious that lie close to the notional threshold (0.62 and 0.58 respectively) suggesting 
that they could be of functional significance. None of the missense polymorphisms were however predicted to 
disrupt any structural or functional sites in the GALC protein. 
Analysis of evolutionary conservation of amino acid residues affected by missense mutations 
    Additional support for the pathological/functional significance of the missense mutations (and potentially 
some of the polymorphisms) identified in the present study, came from the analysis of the extent of evolutionary 
conservation of the mutated residues in 9 orthologous (vertebrate) GALC proteins. The computational analysis, 
carried out at http://www.ensembl.org/, revealed that all 18 missense mutations occurred at amino acid residues 
which were evolutionarily conserved in chicken as well as in various mammals. Further, eleven of the residues 
involved (including those harbouring the novel p.P318R, p.G323R and p.Y490N mutations) were invariant even 
when zebrafish was considered (Supp. Table S4).    
 When a similar analysis was performed on the missense polymorphisms (Supp. Table S5), one of the two SNPs 
predicted by MutPred to be potentially deleterious (p.A21P) was found to occur in a residue which was conserved 
in 5 vertebrates and hence could therefore be of functional significance. However, residue 641, which harbours the 
other potentially functional p.T641A (T625A) SNP, was not evolutionarily conserved. The relationship between 
MutPred values and residue evolutionary conservation therefore appears to be rather more tenuous in the case of 
the missense polymorphisms than it is for the missense mutations. Thus, the residue harbouring the D248N E1902  Tappino et al. 
(D232N) SNP was conserved in 7 vertebrates including the three-spined stickleback, Gasterosteus aculeatus, even 
although its MutPred score was 0.52 (whilst residue 562, harbouring the p.I562T SNP allele (MutPred score 0.53), 
was not evolutionarily conserved). Intriguingly, this latter SNP was present in all three patients with an unknown 
GALC allele but, since it is also present in 14 other patients, it is not possible to draw any firm conclusions as to its 
possible functional significance. 
Consequences of GALC mutations for mRNA processing 
  Reverse transcript-polymerase chain reaction (RT-PCR) analysis was used, wherever possible, to investigate 
frameshift, nonsense and splicing mutations to assess their effect on GALC mRNA processing.  
Frameshifts and stop codons 
A total of 6 microdeletions, 2 insertion/deletions (indels) and 2 microduplications were identified during the 
course of this study. Most were explicable in terms of slipped mispairing between direct repeats or through the 
deletion of a single base within a mononucleotide tract (see Supp. Table S6). Nine of these mutant alleles (seven 
previously unreported) resulted in frameshifts and were therefore analysed by RT-PCR. Although the analyses 
revealed RT-PCR products of a size equivalent to that expected of the wild-type in the case of p.E136EfsX35, 
p.Y174LfsX3, p.H391IfsX65 and p.L469YfsX22, no product was present when the results were evaluated for 
p.A21RfsX51, p.G102GfsX5 and p.G609GfsX6 (data not shown). One explanation for these findings could be that 
the latter three premature stop codons elicited nonsense-mediated mRNA decay (NMD) and hence the 
corresponding abnormal transcripts would have undergone degradation [Nicholson et al, 2010].  
  RT-PCR analyses were also performed to analyse transcripts bearing the three novel stop codons (p.R69X, 
p.K88X and p.R127X). Whereas the transcript harbouring p.R127X appears to be unstable (since the GALC 
mutation in trans and the associated SNPs were invariably found in apparent homozygosity in patient #16), the 
transcript harbouring p.R69X was found to be expressed. The situation pertaining with the p.K88X mutation 
(occurring in trans to p.Y490N in patient #17) was however found to be more complex in that it also impacts on 
splicing. An RT-PCR-fragment spanning exons 1-6 of the GALC gene yielded two products in this patient, one of 
the expected size (630 bp), probably carrying the p.Y490N missense mutation, and one smaller (561 bp). Both 
fragments were cloned and sequenced; although the 603 bp fragment did not exhibit any alteration within the 
region analysed, the smaller 561 bp fragment was found to contain a 69 bp in-frame deletion corresponding to the 
entire length of exon 2 (Figure 2). It would appear that the c.262A>T transversion, occurring in the first base of the 
last codon (AAG) in this exon, affects one of the variant donor splice sites of exon 2, introducing a premature stop 
codon at its last residue (K88X). Although it is likely that the mutation directly abrogated the canonical exon 2 
donor splice site, it is also possible that the splicing machinery acted so as to restore the open reading frame simply 
by removing exon 2 in its entirety [Nissim-Rafinia and Kerem, 2002]. 
 
 
 Table 2: Characteristics of the GALC gene gene mutations identified in the 30 Krabbe disease patients  and  MutPred analysis of the missense mutations 
Locat ion 
Site of nucleotide 
substitution* 
Amino acid 
change* *  
Traditional numbering  
nucleotide (amino acid) substitution   
Type of 
mutation 
MutPred analysis of missense mutations # 
References  Probability of 
deleterious 
mutation  
Confident in silico hypotheses 
Ex. 1 
c.61delG p.A21RfsX51    Frameshift  .     Present  study 
c.175G>C  p.G59R  127G>C  (G43R)  Missense  0.92  None  Fu et al. (1999) 
Ex. 2 
c.205T>C p.R69X    Nonsense  .     Present  study 
c.236G>A  p.R79H  188G>A (R63H)  Missense  0.85  None  De Gasperi et al. (1996) 
c.262A>T p.K88X    Nonsense  .     Present  study 
Ex. 3  c.302_308dupAAATAGG p.G102GfsX5    Frameshift  .     Present  study 
Ex. 4 
c.379C>T p.R127X    Nonsense  .     Present  study 
c.388G>A p.E130K  340G>A  (  E114K)  Missense  0.80 
Gain of molecular recognition feature (MoRF) binding 
(P=0.0047), Gain of methylation at E130 (P=0.0114), 
Gain of ubiquitination at E130 (P=0.0269) 
Lissens et al. (2007) 
c.408delA p.E136EfsX35    Frameshift  .     Present  study 
Ex. 5 
c.521delA p.Y174LfsX3    Frameshift  .     Present  study 
c.560A>T  p.D187V  512A>T (D171V)  Missense  0.71  None  Luzi et al. (1996) 
Ex. 7  c.749T>C  p.I250T  701T>C (I234T)  Missense  0.79 
Gain of protein disorder (P=0.0309), Loss of beta 
sheet secondary structure (P=0.0392) 
De Gasperi et al. (1996) 
Ex. 8 
c.857G>A  p.G286D  809G>A (G270D)  Missense  0.98  None  Furuya et al. (1997) 
c.884A>C  p.N295T  836A>C (N279T)  Missense  0.80  None  Wenger et al. (1997) 
c.918C>T  p.S303F  870C>T (S287F)  Missense  0.83  None  Wenger et al. (1997) 
Ex. 9 
c.941A>G  p.Y314C  893A>G (Y298C)  Missense  0.89  None  De Gasperi et al. (1996) 
c.953C>G p.P318R    Missense  0.79 
Increased solvent accessibility (P=0.0179), Loop > 
Helix secondary structure change (P=0.0259) 
Present study 
c.967G>A p.G323R    Missense  0.91 None Present  study 
Ex. 10 
c.1075_1084delAAGACAGTTG p.K359AfsX3 
1027_1036delAAGACAGTTG
§ 
(K343AfsX3) 
Frameshift . 
 
Wenger et al. (1997) 
c.1151T>C p.I384T    Missense  0.74 None Present  study 
Intr. 10  c.1161+6532_ polyA+9Kbdel  IVS10del30kb  Deletion  .     Rafi et al.(1995) 
Ex.11 
c.1171_1175delCATTCinsA p.H391IfsX65    Frameshift  .     Present  study 
c.1186C>T  p.R396W  1138C>T (R380W)  Missense  0.96  Loss of protein disorder (P = 0.0371)  Wenger et al. (1997) 
c.1187G>T  p.R396L  1139G>T (R380L)  Missense  0.95  Gain of ubiquitination at K393 (P = 0.0452)  Selleri et al. (2000) 
Ex. 13 
c.1405_1407delCTCinsT p.L469YfsX22    Frameshift  .     Present  study 
c.1468T>A p.Y490N    Missense  0.68  Loss of phosphorylation at Y490 (P=0.0245)  Present study 
Intr. 13  c.1489+1G>A p.S488NfsX200    Splicing  .     Present  study 
Ex. 14 
c.1586C>T  p.T529M  1538C>T (T513M)  Missense  0.68  None  Wenger et al. (1997) 
c.1657G>A  p.G553R  1609G>A (G537R)  Missense  0.91  Sheet > Helix secondary structure change (P=0.0151)  De Gasperi et al. (1999) 
Ex. 15 
c.1700A>C  p.Y567S  1652A>C (Y551S)  Missense  0.73  None  Wenger et al. (1997) 
c.1787delT  p.F596SfsX16  1739delT (F580SfsX16)  Frameshift  .     Selleri et al. (2000) 
c.1819_1826dupGTTACAGG p.G609GfsX6    Frameshift  .     Present  study 
Ex. 16  c.1901delT  p.L634X  1853delT (L618X)  Nonsense  .     Wenger et al. (1997) 
Legend: Ex=exon; Intr=intron; *GALC gene GenBank-EMBL accession no. NM_000153.2; **GALC gene GenBank-EMBL accession no. NP_000144.2; the novel mutations are given in bold; 
§mutation  reported as 
c.1026del10 by Rafi et al., unpubished observations [Wenger et al., 2007]. 
 #Li et al., (2009) and Mort et al., (2010). 
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Figure 2. RT-PCR on patient (Pt) #17 [p.K88X]+[p.Y490N]. A: RT-PCR analysis performed on the RNA sample using primers 
encompassing exons 1-6 (Supp. Table S1), revealing the presence of an abnormally shorter GALC transcript (561-bp) in addition to 
the normally-sized product (630-bp). B: The graphical representation of the result, confirmed by sequencing the two cloned products. 
The analysis demonstrated normal splicing (unbroken red line) of the 630-bp fragment and abnormal splicing (dotted red line) of the 
561-bp product resulting in a 69-bp in-frame deletion corresponding to the entire exon 2 of GALC in the shorter product. The 
AAG>TAG transversion, affecting the last codon of exon 2, is given. Note that only exons 1, 2 and 3 are graphically shown. M, 
marker = ϕX 174 DNA HaeIII-digested; C1, C2, C3 = control samples. 
 
Splicing mutation  
To confirm the pathological authenticity of the intronic mutation c.1489+1G>A, RT-PCR analysis was performed on 
the mRNA of patient #20. In this patient, the mutation occurred in trans to the rare microdeletion c.1901delT 
(1853delT) that was predicted to introduce a premature stop codon at residue 634 (p.L634X) (L618X) (Table 1). The 
c.1489+1G>A transition, occurring within the invariant GT dinucleotide of the intron 13 donor splice-site, was expected 
to lead to the skipping of exon 13 by abolishing the canonical splice site. However, contrary to expectation, RT-PCR 
analysis of GALC RNA from the patient (using a primer set spanning exons 10-17, as reported in Supp. Table S1) 
revealed the presence of an abnormally short transcript in addition to the normally-sized 1089 bp products (data not 
shown), both of which were cloned and sequenced. Although sequence analysis of the two RT-PCR products confirmed 
the presence of the microdeletion c.1901delT in the apparently normally-sized cDNA product, only partial skipping of 
exon 13 was evident, with the shorter transcript lacking the last 27 nucleotides (c.1463_1489) (Figure 3). The junction 
between nucleotides c.1462 (exon 13) and c.1490 (exon 14) at the new donor splice-site (probably mediated by the use 
of the cryptic exonic GT dinucleotide at c.1463-1464), gave rise to a serine to asparagine substitution at residue 495 
followed by a frameshift that is predicted to lead to the premature termination of translation (p.S488NfsX200). 
 
 
Figure 3. Schematic 
representation of the 
abnormal  GALC splice 
variant in patient #20.   
In the top half of the 
diagram (A), red dotted 
lines represent the 
aberrant splicing event 
which results from the 
c.1489+G>A mutation 
within the invariant gt 
dinucleotide at the 
5’splice site (ss) 
(marked by a red 
arrow). As a 
consequence of the 
aberrant splicing event, the junction between nucleotides c.1462 (exon 13) and c.1490 (exon 14) occurs at a novel donor splice site, 
almost certainly mediated by the use of the exonic (underlined) GT dinucleotide at c.1463-1464. In the bottom half of the diagram 
(B), a sequence analysis chromatograph of an RT-PCR product from the patient shows the aberrantly non-canonical exon 13-14 
junction at c.1462-c.1490 instead of c.1489-c.1490, consequent to the loss of 27 nucleotides (red type). Green boxes denote the 
portion of the genomic sequence of exons 13 and 14 that is presented in the chromatograph (B); the pink box denotes the skipped 27 
nucleotides of exon 13. The black dotted line represents intron 13. GALC Gene Mutations  E1905 
 
 
Insights into the genotype-phenotype relationship in Krabbe disease 
  Table 1 summarizes the clinical phenotypes of the 30 Krabbe disease patients, most of whom presented with the 
clinically severe infantile form. Owing to the highly heterogeneous GALC mutational profile, it is difficult to discern 
any general trends in terms of a genotype-phenotype relationship. In addition to the mutational heterogeneity, the highly 
variable polymorphic background manifested by each patient (Supp. Table S3) could also play a role in modulating the 
genotype-phenotype relationship.  
  Consistent with previous studies, the common 30kb deletion (c.1161+6532_polyA+9kbdel) was invariably found in 
cis to c.550T (502T), and frequently in patients with the infantile form of the disease (but sometimes also with the 
juvenile form, depending on the precise combination with the other mutant alleles). Our series of patients also provided 
support for previous speculation that the p.G286D (G270D) mutation might be associated specifically with the 
juvenile/mild forms of Krabbe disease [Furuya et al., 1997; De Gasperi et al., 1999]. Indeed, the juvenile form of the 
disease in patient #26 (Table 1), carrying the large 30kb deletion (c.1161+6532_polyA+9kbdel) on one GALC allele, 
may have been consequent to the contribution of the putatively milder p.G286D (G270D) lesion on the second allele. 
Further evidence to support the less deleterious nature of this missense mutation was provided by the adult form of the 
disease in patient #30 (Table 1) in whom p.G286D (G270D) occurred in trans to the novel (and probably highly 
deleterious) p.P318R mutation. The replacement of a cyclic uncharged proline (P) with a basic charged arginine (R) in 
position 318 was predicted by MutPred to impact upon protein structure both in terms of solvent accessibility (P = 
0.0179) and secondary structure (loop → helix; P = 0.0259) (Table 2). Another in silico hypothesis was available for the 
novel missense mutation p.Y490N: the non-conservative substitution of tyrosine (Y) by asparagine (N) is predicted to 
lead to the loss of a phosphorylation site at residue 490 (P = 0.0245), consistent with the severe infantile form of the 
patient #17 (Table 1). The second allele in this patient (#17) is the nonsense mutation (p.K88X), discussed above, that 
predicts premature termination of translation at codon 88.  
  In accordance with in vitro expression studies which indicated that no GALC enzymatic activity was evident in 
association with p.G553R (G537R) [De Gasperi et al., 1999], MutPred analysis postulated a change in the alpha-helical 
secondary structure as consequence of the replacement of a glycine with an arginine at residue 553. Consistent with this 
prediction, we found this mutation in association with the severe infantile form of the disease either in homozygosity 
(Table 1, pts #3, #14, #19) or compound heterozygosity (Table 1, pts #4, #11, #16). Only once was p.G553R (G537R) 
found in association with a late-onset form of the disease (Table 1, pt #29); in this case, the less severe phenotype was 
probably due to the contribution of p.R79H (R63H) on the second allele, confirming an already reported association 
with the late-onset form of the disease [De Gasperi et al., 1999].  
  The third most frequent mutation, p.N295T (N279T), was found in two infantile onset patients (#8 and #15) in 
trans to p.E130K (E114K) and the common large 30kb deletion, respectively. The same p.N295T (N279T) mutation 
was also found in compound heterozygosity in a patient (#28) with the juvenile form of the disease, in association with 
the novel frameshift mutation, p.G609GfsX6. These observations are not only suggestive of a highly detrimental effect 
for the p.E130K (E114K) mutation (first reported by Lissens et al., 2007) but also allow us to postulate a less severe 
phenotype in association with the novel frameshift mutation, p.G609GfsX6.  
  Finally, examination of our patient series revealed a possible association with the juvenile form of the disease for 
the novel missense mutation p.I384T, found in patient #27 (Table 1) in trans to the novel nonsense p.R69X mutation 
(expected to introduce a premature termination codon; see above).  
  To conclude, despite the highly heterogeneous mutational and polymorphic profiles of the GALC gene, studies on 
our large series of Krabbe disease patients have provided support for various (previously somewhat tentative) genotype-
phenotype correlations that were based on relatively small numbers of patients with extremely rare mutations. In 
addition, the present data suggest that the GALC mutational spectrum underlying Krabbe disease in the Italian 
population is somewhat different from that reported in other patient cohorts with European ancestry. This appears to be 
due, at least in part, to a prevalent GALC missense substitution p.G553R (G537R) whose high frequency appears to be 
due to a founder mutation. Other known examples of GALC founder mutations include the large common deletion 
(c.1161+6532_polyA+9kbdel) thought to have originated in Sweden [Wenger et al., 1997], the two mutations c.1796>G 
and c.1630G>A (1748T>G and 1582G>A) present in the Druze and Moslem Arab populations [Rafi et al., 1996] and 
c.169G>A (121G>A), which has been reported as being responsible for the high incidence of Krabbe disease in a 
restricted geographical area of southern Italy (Catania, Sicily) [Lissens et al., 2007].   
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 Supp. Table S1: List of primers used for polymerase chain reaction (PCR) amplification of GALC gene exons and exon–intron boundaries
Exons 
amplified
5’ sequence 
flanking exon 
(bp) 
Forward (5'>3')*   Reverse (5'>3')* 
3’ sequence
flanking exon 
(bp) 
Annealing 
Temperature (°C) 
PCR product 
size (bp) 
Genomic DNA Amplification
§ 
1    86 #  GTCAGCATCAGCGGCCTCCT  ACTGGCACCCTAGGGGAAT  134  62  415 
2-3  169  CAATGATTGGCACAGAAAGG  TCACAGTCCATATGCTGAGGT  70  58       619 ** 
4 72  GGTGGGGAGTGAGATGGTC  CAAGGGCAAAGAAAGGATCA  172  58  359 
5 64  TATTTTCAATAGCGCCAGCA  GCAAAGGGGAGCAATTAAAG  131  50  381 
6 71  TCGTAACGATAATCTGCTTTCTG  GGTATTTCCAACACAAATTTCC  101  60  211 
7 77  ATCTTGGTCATAAATTCAACAGC  GAGAATGTAATCAAATGGGGAGA  98  60  305 
8 182 TGCTGAGACAAAAGGGCATA  GATGACGCTAACAAGGCAAA  133  58  471 
9 131 TTGGGTGATCCTTTTATTGTCA    CACTGGCAAATCTTGCTTAAAA    140  58  397 
10 106  GTTTGGATGAATCAGACTCAAAT  TGGCATCTGTCTGTATGCTTATG  116  58  350 
11 97  AAATTTCTGTTAATCTTGGGCATT  GAACTACTGGCCTGTGACAGAA  73  60  259 
12 81 TCTTGCTGGTACTGATTTTGGA  TGACATTTCTGTGCCCTTTT  71  60  239 
13 63  TTCTGTCCACATGAGATGAGC  CATCATGCACCCAGTTTGAC  86  60  300 
14 60  AGCAAGGAGAGCTTCTGAAGGA  AGGTTCTTGAAATAGGAGGACCA  107  60  347 
15 154  TCTTGAAGCCCATCTCTGCT  TGCTTACATCCCTTCCCAAT  108  60  456 
16 86  CCACTCAAGAACCCCACTGA GTCACACTTTCCCCCTCCTA  94  60  256 
17  140  GGAATTGTGTTTTGCTGTGG  ACCAGTTTTCCCCTTGGAAT       200 ##  60  487 
cDNA Amplification° 
1-6    GAGTCATGTGACCCACACAA TTGGCATTATATGACCTCTCAT    62  630 
1-10   GAGTCATGTGACCCACACAA  TAAGCCATCAGTCAGAGCTACG        65  1150 
10-17   AGTTTACTCAACCTGGCTGG  AACAAGAATTGGCTCTGAACC    59  1089 
§GALC gene: GenBank-EMBL accession no. NC_000014.8 ; °GALC cDNA GenBank-EMBL accession no. NM_000153.2; * the primers are located 5’ (upstream) and 3’ (downstream) to the  
intronic sequences flanking each exon; **in this case, the size also includes  intron 2; part of genomic region at 5’ UTR (#) and 3’ UTR (##) 
 
E1908  Tappino et al.  
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Supp. Table S2: Oligonucleotide primers used for PCR amplification of the novel missense mutations and polymorphisms 
Location    Forward (5'>3')
#  Reverse (5'>3')
# 
Annealing 
Temperatur
e (°C) 
PCR 
product 
size (bp) 
Restriction 
enzyme 
Mutation
§ 
Ex. 9  c.953C>G  TTGGGTGATCCTTTTATTGTCA   CAACCCGCATCTCCCATGA*  58 195  Mnl   I 
Ex. 9  c.967G>A            AGTTGCCTTATGGGAGCTGC*  CACTGGCAAATCTTGCTTAAAA   60  229  Pst I 
Ex. 10  c.1151T>C  GTTTGGATGAATCAGACTCAAAT ACAAAAGTTTACCATGGTTCCA*   56  246  Bsr I 
Ex. 13  c.1468T>A           TTCTGTCCACATGAGATGAGC  CCAACATTGAAATCCACCTTAT*   59  215  Bst x I 
          
Polymorphism
§ 
UTR 5’   c.42GC  GCTTCCTGGCAACGCCGATC*   ACTCATGGCCCTCTTCCTTT  62  309  Taq I 
Ex. 1  c.61GC  GTCAGCATCAGCGGCCTCCT ACTCATGGCCCTCTTCCTTT 62 415  Sma  I 
Ex. 1  c.75CA  GTCAGCATCAGCGGCCTCCT ACTCATGGCCCTCTTCCTTT 62 415  Hga  I 
Intr. 1  c.195+34GT  GTCAGCATCAGCGGCCTCCT ACTCATGGCCCTCTTCCTTT 62 415  Bbv  I 
Intr. 7  c.752+56TC  ATCTTGGTCATAAATTCAACAGC  GAGAATGTAATCAAATGGGGAGA  60  305  Taq I 
Legend: Ex=exon, Intr=intron; 
 §GALC gene GenBank-EMBL accession no. NM_000153.2 and no. NC_000014.8 ; *primer modified so as to introduce a 
new restriction enzyme cleavage site according to Schwartz et al. (1991) 
 E1910  Tappino et al. 
Supp. Table S3: Characteristics of putatively neutral SNPs identified in the GALC gene  
MutPred analysis 

Position  dsSNP  
rs no. 
Traditional numbering  
nucleotide (amino acid) 
substitution    
Site of nucleotide substitution* 
(amino acid change)** 
Minor allele 
frequency 
§ Probability of 
deleterious mutation 
Confident  
in-silico 
hypotheses  
Polymorphic background in the Patients # 
UTR 5'      c.42GC (p.A14A)  0.22  .   10,11,16 
Ex. 1      c.61GC (p.A21P)  0.15  0.62 None  10,16 
Ex. 1      c.75CA  (p.G25G)  0.11  .   10,11,16 
Intr. 1     c.195+34GT  0.17  .   10,16 
Intr. 2  rs2245387 216+108GA    c.264+108GA  0.48  .    5,6,7,8,15,18,21,22,24,25,27,28 
Intr. 3     c.328+19TA NA .    10 
Ex. 4  rs11552556  282CT (D94D)  c.330CT (p.D110D)  NA  .    23,30 
Ex. 5  rs1805078  502CT (R168C)  c.550CT (p.R184C)  0.47  0.38  None  1,7,9,10,12,15,18,23,24,26 
Ex. 7  rs34362748  694GA (D232N)  c.742GA (p.D248N)  0.09  0.52  None  10,16 
Intr. 7     c.752+56TC  0.13  .   16 
Ex. 9  rs12888666  936GA (Q312Q)  c.984GA (p.Q328Q)  0.48  .    5,6,7,8,15,18,21,22,24,25,27 
Ex. 10  rs74073730  1024CT (L342L)  c.1072CT (p.L358L)  NA  .    3,4,11,14,16,19,29 
Intr. 10  rs17687109 1113+38TC  c.1161+38TC  0.08  .    10 
Intr. 10  rs11300320 1114-4delT  c.1162-4delT  NA  .    1,4,7,8,13,15,16,17,18,21,24,30 
Intr. 12  rs74076317 1290+23TC  c.1338+23TC  NA  .    3,4,11,14,16,19,29 
Ex. 13  rs398076  1302CT (S434S)  c.1350CT (p.S450S)  0.44  .    1,2,6,11,12,13,17,18,21,23,24,25,26,27,28,29,30 
Ex. 14  rs367327  1572GA (T524T)  c.1620GA (p.T540T)  0.15  .    1,2,5,6,7,8,9,10,11,13,15,16,17,18,19,20,21,22,23,24,25,28,29 
Ex. 14  rs9672064  1584TC (D528D)  c.1632TC (p.D544D)  NA  .    19 
Intr. 14  rs366615 1622+60CT  c.1670+60CT  0.48  .    1,4,9,11,19,21,22,24,27,29 
Intr. 14  rs12432149 1623-15CT  c.1671-15CT  0.48  .    5,7,8,10,15,16,17,20,21,22,24,25,27,28,29,30 
Ex. 15  rs398607  1637TC (I546T)  c.1685TC (p.I562T)  0.47  0.53  None  1, 2,4,6,9,12,13,17,21,22,23,24,25,27,28,29,30 
Ex. 15  rs421466  1650AT (V550V)  c.1698AT (p.V566V)  0.17  .    1, 2,4,5,6,7,8,9,10,11,12,13,15,16,17,18,20,21,22,23,25,28,29,30 
Intr. 15  rs448805 1786+5CG  c.1834+5CG  0.19  .    1,4,8,11,16,28,29,30 
Ex. 17  rs421262  1873AG (T625A)  c.1921AG (p.T641A)  0.17  0.58  None  1,2,4,5,6,7,8,9,10,11,12,13,15,17,18,20,21,22,24,25,28,29,30 
Legend: dbSNP, the Single Nucleotide Polymorphism database, is available at http://www.ncbi.nlm.nih.gov/projects/SNP/; *GenBank-EMBL accession no. NM_000153.2;  **GenBank-EMBL accession no. NP_000144.2;  
 
§the minor allele frequencies were available at dbSNP  or calculated  from 200 Italian control alleles (novel polymorphisms, in bold) ; NA: not available; #patient number  according to Table 1. 
 Li et al., (2009) and Mort et 
al., (2010). GALC Gene Mutations  E1911 
 
 
 
Supp. Table S4. Evolutionary comparison of the protein sequences flanking the missense mutations  identified in the 
human   GALC protein with their orthologous counterparts in nine eukaryotes 
                                                                                                                                                                                                            G79R   
Homo sapiens  MAEWLLSASWQRRAKAMTAAAGSAGRAAVPLLLCALLAPGGAYVLDDSDGLGREFDGIGA 
Pan troglodytes  MAEWLLSASWQRRAKAMTAAAGSAGRAAVPLLLCALLAPGGAYVLDDSDGLGREFDGIGA 
Canis familiaris  MAERPLQASRQRRGKAMTAAAGSAGHAAVPLLLCALLVPGGAYVLDDSDGLGRELG--GW 
Bos taurus  MAERLIQASWQRRAKAMTAAAGLAGQAAVPLLLCALLAPSGAYVLDDSEGLGREFDGIGA 
Mus musculus  MANSQPKASQQRQAKVMTAAAGSASRVAVPLLLCALLVPGGAYVLDDSDGLGREFDGIGA 
Rattus norvegicus  MANSRPKASQQRQAKVMTAAAGSASRVAVPLLLCAMLAPSGAYELDDSDGLGLEFDGIGA 
Gallus gallus  ------------------------------------------------------------------------------VGAAYVLDDAGGLGREFDGIGA 
Xenopus tropicalis  --------------------TVLAGSRRAPGCGEGMFILWLVLLLFPG--APAQYSVDDLGGLGRMFDGIGA 
Gasterosteus aculeatus  -------------------------------------MFGGNELCVILCDHFILTGARGSCPPYNLSDARGLGRTFDGIGG 
Danio rerio  -----------------------------------------MYIGNQFCVFLSIFLYISG--CLGENYDIDDSLGLGQTFDGIGG 
                                                                                              R79H 
Homo sapiens  VSGGGATSRLLVNYPEPYRSQILDYLFKPNFGASLHILKVEIGGDGQTTDGTEPSHMHYA 
Pan troglodytes  VSGGGATSRLLVNYPEPLRSQIL—YLF—NFGASLHILKVEIGGDGQTTDGTEPSHMHYA 
Canis familiaris  AEGGGATSRLLVNYPEPYRSQILDYLFKPNFGASLHILKVEIGGDGQTTDGTEPSHMHYA 
Bos taurus  VSGGGATSRLLVNYPEPYRSEILDYLFKPNFGASLHILKVEIGGDGQTTDGTEPSHMHYA 
Mus musculus  VS--GGATSRLLVNYPEPYRSEILDYLFKPNFGASLHILKVEIGGDGQTTDGTEPSHMHYE 
Rattus norvegicus  VS-GGGATSRLLVNYPEPYRSEILDYLFKPNFGASLHILKVEIGGDGQTTDGTEPSHMHYE 
Gallus gallus   IS-GGGATSRLLVNYQEPYRSQILDYLFKPNFGASLHILKVEIGGDGQSTDGTEPSHMHYP 
Xenopus tropicalis  IS-GGGATSRLLVNYPEPQRTEILDYLFKPNFGASLHIFKVEIGGDAQTTDGTEPSHMHY 
Gasterosteus aculeatus  LS-GGGATSRLLVNYAEPFRSQILDFLFTPGFGASLHILKVEIGGDAQSTDGTEPSHMHHE 
Danio rerio  LS-GGGATSRLLVNYEEPYQSQILDYLFKPKFGASLQILKVEIGGDAQTTDGTEPSHMHYE 
                                                                     E130K 
Homo sapiens  LDENYFRGYEWWLMKEAKKRNPNITLIGLPWSFPGWLGKGFDWPYVNLQLTAYYVVTWIV 
Pan troglodytes  LDENYFRGYEWWLMKEAKKRNPNITLIGLPWSFPGWLGKGFDWPYVNLQLTAYYVVTWIV 
Canis familiaris  LDENFFRGYEWWLMKEAKKRNPNIILMGLPWSFPGWIGKGFNWPYVNLQLTAYYIMTWIV 
Bos taurus  LDENYFRGYEWWLMKEAKKRNPNITLIGLPWSFPGWLGKGFNWPYVNLQLTAYYIVTWIV 
Mus musculus  LDENYFRGYEWWLMKEAKKRNPDIILMGLPWSFPGWLGKGFSWPYVNLQLTAYYVVRWI 
Rattus norvegicus  LDENYFRGYEWWLMKEAKKRNPNIILMGLPWSFPGWLGKGFSWPYVNLQLTAFYIVRWIL 
Gallus gallus  NDENYFRGYEWWLMKEAKKRNPQIKLIGLPWTFPSWIGKGEDWPYDYPHVTVYYIISWIL 
Xenopus tropicalis  DDQNYFRGYEWWLMKEAKKRNPAIKLIGLPWAFPGWIGNGKNWPYDFPDVTAYYVVSWII 
Gasterosteus aculeatus  DDENYFRGYEWWLMKEAKKRNPNITLMSLPWAFPGWVGHGKNWPYDFPDITAAYVVNWIL 
Danio rerio  DDENYFRGYEWWLMVEAKKRNPNITLIGLPWAFPGWVGNGKNWPYDFPDITASYVVAWIH 
                                                            D187V 
Homo sapiens  GAKRYHDLDIDYIGIWNERSYNANYIKILRKMLNYQGLQRVKIIASDNLWESISASMLLD 
Pan troglodytes  GAKRYHDLDIDYIGIWNERSYNANYIKILRKMLNYQGLQRVKIIASDNLWESISASMLLD 
Canis familiaris  GAKHYHDLDIDYIGIWNERSFDINYIKVLRRMLNYQGLDRVKIIASDNLWEPISASMLLD 
Bos taurus  GSKHYHDLDIDYIGIWNERAFDINYIKVLRRMLNHQGLQHVKIIASDNLWEPISASMLLD 
Mus musculus  GAKHYHDLDIDYIGIWNERPFDANYIKELRKMLDYQGLQRVRIIASDNLWEPISSSLLL 
Rattus norvegicus  GAKHYHDLDIDYIGIWNERPFDANYIKELRKMLDYEGLQRVRIIASDNLWEPISSSVLL 
Gallus gallus  GAKQYHDLDIDYIGIWNERAFNSKYIKLLRYTLDKNGLQKVRIIASDRLWEPISFVMLI 
Xenopus tropicalis  GAKQYHNLDIDYIGIWNERAYDIKYIKVLRHTLDRLGLTNVGIITADGDWE-IAHDVLV 
Gasterosteus aculeatus  GAKQYHDLDIQYVGIWNERSYDSKYIKLLRYTLDKRGLETVRIVASDNLWEPVVRSVLL 
Danio rerio  GAKKYHDLDIDYIGIWNEKSFNVKYIKLLRYLLDKRGLEKVKIIASDDLWEPITSAVFA 
                                                                         I250T                                                                                                         G286D             
Homo sapiens  AELFKVVDVIGAHYPGTHSAKDAKLTGKKLWSSEDFSTLNSDMGAGCWGRILNQNYINGY
Pan troglodytes  AELFKVVDVIGAHYPGTHSAKDAKLTGKKLWSSEDFSTLNSDMGAGCWGRILNQNYINGY
Canis familiaris  SELLKVIDVIGAHYPGTHTVKDAKLTKKKLWSSEDFSTLNSDVGAGCLGRILNQNYVNGY
Bos taurus  PELLKVIDVIGAHYPGTLTVKDARLTKKKLWSSEDFSTVNGDMGAGCWGRILNQNYVNGY
Mus musculus  QELWKVVDVIGAHYPGTYTVWNAKMSGKKLWSSEDFSTINSNVGAGCWSRILNQNYINGN
Rattus norvegicus  QELWKVVDVIGAHYPGTYTVWNAKMSGKKLWSSEDFSTVNSNVGAGCWGRILNQNYINGN
Gallus gallus  SELHEVVDVIGAHYPGTKTVPNALLTQKKLWASEDYSTFNDEVGAGCWARILNQNYVNGN
Xenopus tropicalis  PYLNEAVQVIGAHYPGTHAAQDAILTGKTLWASEDYSTYNDEVGGGCWARILNQNYVNGN
Gasterosteus aculeatus  PELSGAVDVIGAHYPGTNSPEEALKTQKKLWASEDYSTFNDEVGGGCWARILNQNYVNGL
Danio rerio  KELYDAIEVLGVHYPGTKTVPRALKTGKKLWSSEDYSTFNDNVGGGCWARILNQNYVNG E1912  Tappino et al. 
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                                                 S303F                  Y314C  P318R   G323R 
Homo sapiens  MTSTIAWNLVASYYEQLPYGRCGLMTAQEPWSGHYVVESPVWVSAHTTQFTQPGWY 
Pan troglodytes  MTSTIAWNLVASYYEQLPYGRCGLMTAQEPWSGHYVVESPVWVSAHTTQFTQPGWY 
Canis familiaris  MTATIAWNLVASYYEQLPYGRCGLMTAQEPWSGHYVVESPIWVSAHTTQFTQPGWY 
Bos taurus  MTSTIAWNLVASYYQQLPYGRCGLMTAQEPWSGHYVVEAPIWVSAHTTQFTQPGWY 
Mus musculus  MTSTIAWNLVASYYEELPYGRSGLMTAQEPWSGHYVVASPIWVSAHTTQFTQPGWY 
Rattus norvegicus  MTATIAWNLVASYYEELPYGRSGLMTAQEPWSGHYVVASPIWVSAHTTQFTQPGWY 
Gallus gallus  MTSTIAWNLVASYYEELPFGRCGLMTAQEPWSGYYKVEAPIWITAHTTQFTQPGWS 
Xenopus tropicalis  MTSTISWNMVASYYEQLPFGLEGLMTAKEPWSGNYVVSTPIWITAHTTQFTQPGWY 
Gasterosteus aculeatus  MTATISWNLVASYYEDLPFSRDGLMTAEEPWSGNYVVESPIWITAHTTQFTQPGWT 
Danio rerio  MTATISWNLVASYYENLPFGRDGIMTANEPWSGNYVVESPVWTTAHTTQFTEPGWT 
                                  I384T                      R396(W)(L) 
Homo sapiens  VGHLEKGGSYVALTDGLGNLTIIIETMSHKHSKCIRPFLPYFNVSQQFATFVLKGSFSEI 
Pan troglodytes  VGHLEKGGSYVALTDGLGNLTIIIETMSHKHSKCIRPFLPYFNVSQQFATFVLKGSFSEI 
Canis familiaris  VGHLEKGGSYVALTDGLGNLTIIVETMSHKQSACIRPFLPYFNVSRQFATFVLKGSFSEI 
Bos taurus  VGHLERGGSYVALTDGLGNLTVIVETMSYKHSKCIRPLLPYFNVSHQFATFDLKGSFSQI 
Mus musculus  VGHLEKGGSYVALTDGLGNLTIIIETMSHQHSMCIRPYLPYYNVSHQLATFTLKGSKGSI 
Rattus norvegicus  VGHLEKGGSYVALTDGLGNFTIIVETMSRQHSMCIRPYLPYYNVSRQLATFILKGSLKEI 
Gallus gallus  VDGHLEGGGSFVALTDGLGNLTIIIETMTHNHSKCIRPPLPHFRVSPQRATFYLRGSFYFL 
Xenopus tropicalis  VGHLDKGGSYVALTDRLGNLTIVIETMSHNNSICIRPPLPDYNVSAQYATFYLQGSFKNL 
Gasterosteus aculeatus  VGHLAQGGSYVALTDGKGNLTVVIETMTRDHSVCIRPPLPPFNVTSQNATFQLEGSFASI 
Danio rerio  VGHFTHGGSYVALTDQRGNLSIITETMTHDHSVCIRPPLRPYNVTVQNVTFNLKGT 
                Y490N                                                                                                     T529M 
Homo sapiens  PKSQPFPSTYKDDFNVDYPFFSEAPNFADQTGVFEYFTNIEDPGEHHFTLRQVLNQRPIT 
Pan troglodytes  PKSQPFPSTYKDDFNVDYPFFSEAPNFADQTGVFEYFTNIEDPGEHHFTLRQVLNQRPIT 
Canis familiaris  PKSEPFPQIYEDDFDVDYPFFSEAPNFADQTGVFEYFTNIEDPGEHRFTLRQVLNQRPIT 
Bos taurus  PKSQRFPSVYEDNFNIDYPFFSEAPNFADQTGVFEYYVNMEDPGDHRFTLRQVLNQRPIT 
Mus musculus  PSSKPFPTNYKDDFNVEYPLFSEAPNFADQTGVFEYYMNNEDR-EHRFTLRQVLNQRPIT 
Rattus norvegicus  PKSQPFPTSYKDDFNVEYPLFSEAPNFADQTGVFEYYTNNEDL-EHRFTLRQVLNQRPIT 
Gallus gallus  PPPQPFPSNYKDDFNIRNPPFSEAPNFADQTGVFEYFVNGSDPGDHVFTLRQVVIQRPIT 
Xenopus tropicalis  PPESKPFPLKYKDDFSVRNPPFSEAPYFADQSGVFEYFTNTSDPGDHVFTFRQVLTQRPIT 
Gasterosteus aculeatus  PPSARFPKVYKDDFNVRNPPFSEAPNFADQTGVFEYYVNMSDPGPHVFTLRQVVTERPIT 
Danio rerio  PPSAPFPKSYRDDFNVSGN-FSEAPNFADQTGVFEYFTNNLTDPGPHVFTLRQVVTRPVT 
                                                                        G553R                            Y567S 
Homo sapiens  WAADASNTISIIGDYNWTNLTIKCDVYIETPDTGGVFIAGRVNKGGILIRSARGIFFWIF 
Pan troglodytes  WAADASNTISIIGDYNWTNLTIKCDVYIETPDTGGVFIAGRVNKGGILIRSARGIFFWIF 
Canis familiaris  WAADAYNTISIIGDYKWSNLTVRCDVYIETPEKGGVFIAGRVNKGGILIRSARGIFFWIF 
Bos taurus  WAADAFNTISVIGDYSWSNLTIKCDVYIETPEKGGVFIAGRVNKGGILIRSARGIFFWIF 
Mus musculus  WAADASSTISVIGDHHWTNMTVQCDVYIETPRSGGVFIAGRVNKGGILIRSATGVFFWIT 
Rattus norvegicus  WAADASSTISVIGDHHWSNMTVQCDVYIETPRTGGVFIAGRVNKGGILIRTASGVFFWIF 
Gallus gallus  WVSDADQTISIIGNFQWVNLTVTCDIYIEKPIDGGVFIAGRVDNGGIYVRRTKGVFFWVY 
Xenopus tropicalis  WASDANQAISVIGNYQWSNVTVTSDIYIETPDTGGVFVAARVDQGGSPTDRAKGIFFWV 
Gasterosteus aculeatus  WAADADQTISVVGDHQWGNLTVTCDVFMERVKTGGVFIAARVDKGGQSVRSARGVFFWV 
Danio rerio  WAADADQTISVIGDYAWHDVMVSCDVYMEAVQTGGVFIAARVDRGGGVIRSTRGV GALC Gene Mutations  E1913 
 
  R184C 
Homo sapiens  GAKRYHDLDIDYIGIWNERSYNANYIKILRKMLNYQGLQRVKIIASDNLWESISASMLLD 
Pan troglodytes  GAKRYHDLDIDYIGIWNERSYNANYIKILRKMLNYQGLQRVKIIASDNLWESISASMLLD 
Canis familiaris  GAKHYHDLDIDYIGIWNERSFDINYIKVLRRMLNYQGLDRVKIIASDNLWEPISASMLLD 
Bos taurus  GSKHYHDLDIDYIGIWNERAFDINYIKVLRRMLNHQGLQHVKIIASDNLWEPISASMLLD 
Mus musculus  GAKHYHDLDIDYIGIWNERPFDANYIKELRKMLDYQGLQRVRIIASDNLWEPISSSLLL 
Rattus norvegicus  GAKHYHDLDIDYIGIWNERPFDANYIKELRKMLDYEGLQRVRIIASDNLWEPISSSVLL 
Gallus gallus  GAKQYHDLDIDYIGIWNERAFNSKYIKLLRYTLDKNGLQKVRIIASDRLWEPISFVMLI 
Xenopus tropicalis  GAKQYHNLDIDYIGIWNERAYDIKYIKVLRHTLDRLGLTNVGIITADGDWE-IAHDVLV 
Gasterosteus aculeatus  GAKQYHDLDIQYVGIWNERSYDSKYIKLLRYTLDKRGLETVRIVASDNLWEPVVRSVLL 
Danio rerio  GAKKYHDLDIDYIGIWNEKSFNVKYIKLLRYLLDKRGLEKVKIIASDDLWEPITSAVFA 
  D248N 
Homo sapiens  AELFKVVDVIGAHYPGTHSAKDAKLTGKKLWSSEDFSTLNSDMGAGCWGRILNQNYINGY 
Pan troglodytes  AELFKVVDVIGAHYPGTHSAKDAKLTGKKLWSSEDFSTLNSDMGAGCWGRILNQNYINGY 
Canis familiaris  SELLKVIDVIGAHYPGTHTVKDAKLTKKKLWSSEDFSTLNSDVGAGCLGRILNQNYVNGY 
Bos taurus  PELLKVIDVIGAHYPGTLTVKDARLTKKKLWSSEDFSTVNGDMGAGCWGRILNQNYVNGY 
Mus musculus  QELWKVVDVIGAHYPGTYTVWNAKMSGKKLWSSEDFSTINSNVGAGCWSRILNQNYINGN 
Rattus norvegicus  QELWKVVDVIGAHYPGTYTVWNAKMSGKKLWSSEDFSTVNSNVGAGCWGRILNQNYINGN 
Gallus gallus  SELHEVVDVIGAHYPGTKTVPNALLTQKKLWASEDYSTFNDEVGAGCWARILNQNYVNGN 
Xenopus tropicalis  PYLNEAVQVIGAHYPGTHAAQDAILTGKTLWASEDYSTYNDEVGGGCWARILNQNYVNGNL 
Gasterosteus aculeatus  PELSGAVDVIGAHYPGTNSPEEALKTQKKLWASEDYSTFNDEVGGGCWARILNQNYVNGL 
Danio rerio  PYLNDAVEVIGVHYPGTNTVKEALLTERKLWSSEDYSTYNDDIGAGCWARILNQNYVNGK 
  I562T 
Homo sapiens  WAADASNTISIIGDYNWTNLTIKCDVYIETPDTGGVFIAGRVNKGGILIRSARGIFFWIF 
Pan troglodytes  WAADASNTISIIGDYNWTNLTIKCDVYIETPDTGGVFIAGRVNKGGILIRSARGIFFWIF 
Canis familiaris  WAADAYNTISIIGDYKWSNLTVRCDVYIETPEKGGVFIAGRVNKGGILIRSARGIFFWIF 
Bos taurus  WAADAFNTISVIGDYSWSNLTIKCDVYIETPEKGGVFIAGRVNKGGILIRSARGIFFWIF 
Mus musculus  WAADASSTISVIGDHHWTNMTVQCDVYIETPRSGGVFIAGRVNKGGILIRSATGVFFWIT 
Rattus norvegicus  WAADASSTISVIGDHHWSNMTVQCDVYIETPRTGGVFIAGRVNKGGILIRTASGVFFWIF 
Gallus gallus  WVSDADQTISIIGNFQWVNLTVTCDIYIEKPIDGGVFIAGRVDNGGIYVRRTKGVFFWVY 
Xenopus tropicalis  WASDANQAISVIGNYQWSNVTVTSDIYIETPDTGGVFVAARVDQGGSPTDRAKGIFFWV 
Gasterosteus aculeatus  WAADADQTISVVGDHQWGNLTVTCDVFMERVKTGGVFIAARVDKGGQSVRSARGVFFWV 
Danio rerio  WAADADQTISVIGDYAWHDVMVSCDVYMEAVQTGGVFIAARVDRGGGVIRSTRGV 
  T641A 
Homo sapiens  ANGSYRVTGDLAGWIIYALGRVEVTAKKWYTLTLTIKGHFTSGMLNDKSLWTDIPVNFPK 
Pan troglodytes  ANGSYRVTGDLAGWIIYALGRVEVTAKKWYTLTLTIKGHFASGMLNDKSLWTDIPVNFPK 
Canis familiaris  ANGTYRVTGDLAGWVIYALGRVDVTAKKWYTLTLIIKGRLSSGMLNGKTVWKNIPVSFPK 
Bos taurus  ANGTYRVTGDLAGWIIYSLGHADVTAKKWYTLTLTLNGRFSSGKLNGKTLWKNISVNFPE 
Mus musculus  ANGSYRVTADLGGWITYASGHADVTAKRWYTLTLGIKGYFAFGMLNGTILWKNVRVKYP 
Rattus norvegicus  ANGSYRVTADLGGWITYASGHADVTAKRWYTLTLGIKGYLASGMLNGKILWENVPVKYP 
Gallus gallus  VYADGTYRVTSDLAGEEILMKGLSGVRHNAWHTLTLNIQGTSASGLLNGYPLWENVTISQ 
Xenopus tropicalis  VFADGTYKVTGDLMGQTILCKGLAGVRARSWHTLTLHIDGTNAFGLLNGNPLWKEVVTGG 
Gasterosteus aculeatus  VFADGTYKVTNDLAGQTVLAEGRSGTRAYGWHTLSLTVAGQYASGLLNGYPLWKNAVVLS 
Danio rerio  VYADGTYKITNDLRGLAVLAKGSAGTRARTWYTLTLRVQGNYASADLNGYSLWKNAVLLN 
Supp. Table S5. Evolutionary comparison of the protein sequences flanking five missense SNPs identified in the human 
GALC protein with their orthologous counterparts in nine eukaryotes  
A21P 
Homo sapiens  MAEWLLSASWQRRAKAMTAAAGSAGRAAVPLLLCALLAPGGAYVLDDSDGLGREFDGIGA 
Pan troglodytes  MAEWLLSASWQRRAKAMTAAAGSAGRAAVPLLLCALLAPGGAYVLDDSDGLGREFDGIGA 
Canis familiaris  MAERPLQASRQRRGKAMTAAAGSAGHAAVPLLLCALLVPGGAYVLDDSDGLGRELG--GW 
Bos taurus  MAERLIQASWQRRAKAMTAAAGLAGQAAVPLLLCALLAPSGAYVLDDSEGLGREFDGIGA 
Mus musculus  MANSQPKASQQRQAKVMTAAAGSASRVAVPLLLCALLVPGGAYVLDDSDGLGREFDGIGA 
Rattus norvegicus  MANSRPKASQQRQAKVMTAAAGSASRVAVPLLLCAMLAPSGAYELDDSDGLGLEFDGIGA 
Gallus gallus  ------------------------------------------------------------------------------VGAAYVLDDAGGLGREFDGIGA 
Xenopus tropicalis  --------------------TVLAGSRRAPGCGEGMFILWLVLLLFPG--APAQYSVDDLGGLGRMFDGIGA 
Gasterosteus aculeatus  -------------------------------------MFGGNELCVILCDHFILTGARGSCPPYNLSDARGLGRTFDGIGG 
Danio rerio  -----------------------------------------MYIGNQFCVFLSIFLYISG--CLGENYDIDDSLGLGQTFDGIGG E1914  Tappino et al. 
Supp. Table S6. Different types of repeats (underlined and highlighted in yellow) that could have 
mediated micro-deletions, micro-insertion/deletions (indel) and micro-duplications in the GALC 
gene.  
Micro-deletion  c.61delG                            direct repeats 
                                                                                                                                                                                     
CGAAAGCTATGACTGCGGCCGCGGGTTCGGCGGGCCGCGCCGCGGTG 
  Ð   
CGAAAGCTATGACTGCGGCC… CGGGTTCGGCGGGCCGCGCCGCGGTG 
                                                                                                                                                                                     
Micro-duplication   c.302_308dupAAATAGG   direct repeats    
                                                                                                                                                                                     
CTTTGCATATTTTAAAAGTGGAAATAGGTGGTGATGGGCA  
  Ð   
CTTTGCATATTTTAAAAGTGGAAATAGGAAATAGGTGGTGATGGGCA 
                                                                                                                                                                                     
Micro-deletion   c.408delA  direct repeats 
                                                                                                                                                                                     
ACGAGTGGTGGTTGATGAAAGAAGCTAAGAAGAGGAATCCCAATATT 
  Ð   
ACGAGTGGTGGTTGATGAAAGA…GCTAAGAAGAGGAATCCCAATATT 
                                                                                                                                                                                     
Micro-deletion   c.521delA     direct repeats 
                                                                                                                                                                                     
TTATGTCAATCTTCAGCTGACTGCCTATTATGTCGTGACCTGGATT 
  Ð  
TTATGTCAATCTTCAGCTGACTGCCTATT…TGTCGTGACCTGGATT                 
                                                                                                                                                                                     
Micro-deletion  c.1075_1084delAAGACAGTTG  direct repeats                                  
                                                                                                                                                                                     
  CTCAGTTTACTCAACCTGGCTGGTATTACCTGAAGACAGTTGGCCATTT 
            Ð   
CTCAGTTTACTCAACCTGG CTGGTATTACCTG…………………GCATTT 
                                                                                                                                                                                     
Micro-indel  c.1171_1175delCATTCinsA   direct repeats                                  
                                                                                                                                                                                     
ATCATCATTGAAACCATGAGTCATAA ACATTCTAAGTGCATACGGCCAT 
  Ð   
ATCATCATTGAAACCATGAGTCATAA AA ……..TAAGTGCATACGGCCAT
  ←←  →           →  
Micro-indel  c.1405_1407delCTCinsT   direct repeats                                  
                                                                                                                                                                                     
TGAGCTGTTCACACTCACCACTCTCTACCACTGGTCGCAAAGGCAGCT 
  Ð   
TGAGCTGTTCACACTCACCACT….TTACCACTGGTCGCAAAGGCAGCT 
                                                                                                                                                                                       
Microdeletion  c.1787delT  mononucleotide tract repeats  
                                                                                                                                                                                     
ATTTTGATTAGAAGTGCCAGAGGAATTTTCTTCTGGATTTTT 
     Ð   
ATTTTGATTAGAAGTGCCAGAGGAATTT…CTTCTGGATTTTT       
                                                                                                                                                                                     
Microduplication  
c.1819_1826dupGTTACAGG 
direct repeats    
                                                                                                                                                                                     
                                  CTTACAGGGTTACAGGTGATTTAGCTGGATGGATTATATATG 
  Ð   
CTTACAGGGTTACAGGGTTACAGGTGATTTAGCTGGATGGATTATATATG   
                                                                                                                                                                                     
Microdeletion  c.1901delT   direct repeats    
                                                                                                                                                                                     
ACAGCAAAAAAATGGTATACACTCACGTTAACTATTAAGGGTCATTTC 
  Ð   
ACAGCAAAAAAATGGTATACACTCACGT…AACTATTAAGGGTCATTTC 
                                                                                                                                                                                     
Mutated nucleotides are shown in bold upper-case red letters. GALC Gene Mutations  E1915 
 
 